Dr. Robert G. Macgregor, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Mercer University School of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 800
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Mercer University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
GA license 067345
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Candler Hospital Savannah, GA
- St Joseph's Hospital - Savannah Savannah, GA
- Savannah Health Services LLC DBA Memorial Health University Medical Center Savannah, GA
Medical groups
- Savannah Neurology Specialists P C (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 800
- Services billed
- 127,335
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 18,295 | 30 |
| Injection, eptinezumab-jjmr, 1 mg | 17,700 | 48 |
| Injection, gadobutrol, 0.1 ml | 1,750 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 527 | 379 |
| Established patient office or other outpatient visit, 20-29 minutes | 395 | 320 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 144 | 33 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 127 | 100 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 103 | 59 |
| Infusion, normal saline solution, 250 cc | 89 | 65 |
| New patient office or other outpatient visit, 45-59 minutes | 88 | 88 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Savannah, GA | 396 |
| Levetiracetam Other prescribers in Savannah, GA | 348 |
| Donepezil Hcl Other prescribers in Savannah, GA | 291 |
| Lamotrigine Other prescribers in Savannah, GA | 192 |
| Memantine Hcl Other prescribers in Savannah, GA | 186 |
| Pregabalin Other prescribers in Savannah, GA | 170 |
| Amitriptyline Hcl Other prescribers in Savannah, GA | 157 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Savannah, GA | 153 |
| Propranolol Hcl Er (propranolol hcl) Other prescribers in Savannah, GA | 131 |
| Baclofen Other prescribers in Savannah, GA | 131 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 39 companies reported 226 payments worth $4,640 in total to this clinician.
| AbbVie Inc. | $484 |
|---|---|
| UCB, Inc. | $389 |
| Biogen, Inc. | $304 |
| Lundbeck LLC | $266 |
| Novartis Pharmaceuticals Corporation | $226 |
| Pfizer Inc. | $218 |
| Neurelis, Inc. | $212 |
| Argenx US, Inc. | $197 |
| Food and Beverage | $4,640 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $19,694 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.